NCOA3 and plasma cell myeloma: Therefore, targeting NSD2 with specific inhibitors could become part of a potential anti multiple myeloma therapy, which by impairing its interaction with SRC-3 (steroid receptor coactivator-3) facilitates overcoming the resistance of multiple myeloma to bortezomid, a proteasome inhibitor [46].